Experimental and emerging therapies for chronic hepatitis C virus infection

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.8, 2001-08, pp. : 1457-1469

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Hepatitis C virus infection is prevalent throughout the world and is associated with substantial morbidity, mortality and health economic burden. No effective preventative measure, including vaccination, is currently available. Incremental and substantial progress in the rate of viral eradication using interferonbased therapies has been made over the past decade. The most recent advance has been related to the development of a pegylated form of IFN-α by two independent pharmaceutical companies. Pegylation of IFNα appears to prolong its halflife, allowing for less frequent dosing. Reports have suggested that pegylated interferons are also associated with better efficacy for viral eradication in patients with hepatitis C virus. Slower progress also has been made in developing noninterferonbased therapeutic agents against hepatitis C virus, including protease inhibitors, helicase inhibitors, ribozymes, antisense therapies, cytokinebased therapies and Tcellbased therapeutic vaccines.